Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2014 2
2015 2
2016 1
2017 1
2019 1
2020 12
2021 6
2022 10
2023 5
2024 2

Text availability

Article attribute

Article type

Publication date

Search Results

41 results

Results by year

Filters applied: . Clear all
Page 1
No Remdesivir Resistance Observed in the Phase 3 Severe and Moderate COVID-19 SIMPLE Trials.
Hedskog C, Spinner CD, Protzer U, Hoffmann D, Ko C, Gottlieb RL, Askar M, Roestenberg M, de Vries JJC, Carbo EC, Martin R, Li J, Han D, Rodriguez L, Parvangada A, Perry JK, Ferrer R, Antón A, Andrés C, Casares V, Günthard HF, Huber M, McComsey GA, Sadri N, Aberg JA, van Bakel H, Porter DP. Hedskog C, et al. Among authors: porter dp. Viruses. 2024 Mar 31;16(4):546. doi: 10.3390/v16040546. Viruses. 2024. PMID: 38675889 Free PMC article. Clinical Trial.
Oral administration of obeldesivir protects nonhuman primates against Sudan ebolavirus.
Cross RW, Woolsey C, Chu VC, Babusis D, Bannister R, Vermillion MS, Geleziunas R, Barrett KT, Bunyan E, Nguyen AQ, Cihlar T, Porter DP, Prasad AN, Deer DJ, Borisevich V, Agans KN, Martinez J, Harrison MB, Dobias NS, Fenton KA, Bilello JP, Geisbert TW. Cross RW, et al. Among authors: porter dp. Science. 2024 Mar 15;383(6688):eadk6176. doi: 10.1126/science.adk6176. Epub 2024 Mar 15. Science. 2024. PMID: 38484056
Characterization of the Cynomolgus Macaque Model of Marburg Virus Disease and Assessment of Timing for Therapeutic Treatment Testing.
Zumbrun EE, Garvey CB, Wells JB, Lynn GC, Van Tongeren S, Steffens JT, Wetzel KS, Gomba LM, O'Brien KA, Rossi FD, Zeng X, Lee ED, Raymond JLW, Hoffman DA, Jay AN, Brown ES, Kallgren PA, Norris SL, Cantey-Kiser J, Kudiya H, Arthur C, Blair C, Babusis D, Chu VC, Singh B, Bannister R, Porter DP, Cihlar T, Dye JM. Zumbrun EE, et al. Among authors: porter dp. Viruses. 2023 Nov 28;15(12):2335. doi: 10.3390/v15122335. Viruses. 2023. PMID: 38140576 Free PMC article.
Expanded profiling of Remdesivir as a broad-spectrum antiviral and low potential for interaction with other medications in vitro.
Radoshitzky SR, Iversen P, Lu X, Zou J, Kaptein SJF, Stuthman KS, Van Tongeren SA, Steffens J, Gong R, Truong H, Sapre AA, Yang H, Xie X, Chia JJ, Song ZJ, Leventhal SM, Chan J, Shornikov A, Zhang X, Cowfer D, Yu H, Warren T, Cihlar T, Porter DP, Neyts J, Shi PY, Wells J, Bilello JP, Feng JY. Radoshitzky SR, et al. Among authors: porter dp. Sci Rep. 2023 Feb 23;13(1):3131. doi: 10.1038/s41598-023-29517-9. Sci Rep. 2023. PMID: 36823196 Free PMC article.
Remdesivir efficacy against yellow fever in a hamster model.
Julander JG, Bunyan E, Jordan R, Porter DP. Julander JG, et al. Among authors: porter dp. Antiviral Res. 2022 Jul;203:105331. doi: 10.1016/j.antiviral.2022.105331. Epub 2022 May 6. Antiviral Res. 2022. PMID: 35533777
41 results